<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203034</url>
  </required_header>
  <id_info>
    <org_study_id>TV-1012/133</org_study_id>
    <nct_id>NCT00203034</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations</brief_title>
  <official_title>A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either
      Rasagiline or Placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean total daily &quot;OFF&quot; time</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">472</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg rasagiline mesylate oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg rasagiline mesylate oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline mesylate</intervention_name>
    <description>0.5 mg rasagiline mesylate oral once daily</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 mg rasagiline mesylate</intervention_name>
    <description>1.0 mg rasagiline mesylate oral once daily</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women with idiopathic Parkinson's disease whose diagnosis is confirmed by at least
        two of the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without
        any other known or suspected cause of parkinsonism.

        Subjects must experience levodopa related motor fluctuations averaging at least 2.5 hours
        daily in the OFF state.

        Subjects must be taking optimized levodopa/carbidopa or levodopa /benserazide
        carbidopa/levodopa therapy (based on investigator's judgment), stable for at least 14 days
        prior to baseline. Subjects must be receiving at least 3 daily doses of levodopa, not
        including a bedtime dose.

        Selegiline must be discontinued for at least 90 days prior to baseline.

        Subject must be age 30 or older.

        Subjects must be willing and able to give informed consent.

        Exclusion Criteria:

        Subjects with a clinically significant or unstable medical or surgical condition which
        would preclude safe and complete study participation. Such conditions may include
        cardiovascular, pulmonary, hepatic, renal, or metabolic diseases or malignancies as
        determined by medical history, physical exam, laboratory tests, chest x-ray, or ECG for
        Parkinson's disease [e.g., pallidotomy, thalamotomy, and deep brain stimulation (DBS)]
        within the 12 months preceding the Baseline visit.

        Subjects who have undergone neurosurgical transplantation are excluded regardless of when
        the procedure(s) was performed. No programming changes are permitted in subjects who have
        undergone DBS.

        Participation in a previous clinical trial of rasagiline. Concomitant therapy with MAO
        inhibitors, reserpine, methyldopa within the past three months, or treatment with an
        anti-emetic or neuroleptic medication with central dopamine antagonist activity with the
        past six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira Shoulson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parkinson Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush - Presbyterian St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia - Presbyterian Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 8, 2010</last_update_submitted>
  <last_update_submitted_qc>March 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, MD, PhD, VP I R&amp;D, Head of Global Clinical Operations</name_title>
    <organization>Teva Branded Pharmaceutical Products IR&amp;D</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

